Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer

Reuters

2025/06/05

Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer

Akeso Inc. has announced a significant regulatory milestone, as the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for cadonilimab (PD-1/CTLA-4). This approval allows the use of cadonilimab in combination with platinum-based chemotherapy, with or without bevacizumab, as a first-line treatment for persistent, recurrent, or metastatic cervical cancer. This marks the third approved indication for cadonilimab and addresses the critical unmet needs for immune-based therapies for cervical cancer patients in China. The approval is based on the successful results of the COMPASSION-16/AK104-303 study, which demonstrated significant improvements in progression-free survival and overall survival.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541904690"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541904690\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541904690?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 08:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541904690","market":"nz","top_or_hot":-1,"title":"Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akeso Inc. has announced a significant regulatory milestone, as the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for cadonilimab (PD-1/CTLA-4). This approval allows the use of cadonilimab in combination with platinum-based chemotherapy, with or without bevacizumab, as a first-line treatment for persistent, recurrent, or metastatic cervical cancer. This marks the third approved indication for cadonilimab and addresses the critical unmet needs for immune-based therapies for cervical cancer patients in China. The approval is based on the successful results of the COMPASSION-16/AK104-303 study, which demonstrated significant improvements in progression-free survival and overall survival.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-05 08:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akeso Inc. has announced a significant regulatory milestone, as the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for cadonilimab (PD-1/CTLA-4). This approval allows the use of cadonilimab in combination with platinum-based chemotherapy, with or without bevacizumab, as a first-line treatment for persistent, recurrent, or metastatic cervical cancer. This marks the third approved indication for cadonilimab and addresses the critical unmet needs for immune-based therapies for cervical cancer patients in China. The approval is based on the successful results of the COMPASSION-16/AK104-303 study, which demonstrated significant improvements in progression-free survival and overall survival.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B543WZ88.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL3qpqQ3:1","article_id":"2541904690","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541904690","pubTimestamp":1749082781,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Akeso Inc. has announced a significant regulatory milestone, as the National Medical Products Administration  of China has approved the supplemental New Drug Application  for cadonilimab . This approval allows the use of cadonilimab in combination with platinum-based chemotherapy, with or without bevacizumab, as a first-line treatment for persistent, recurrent, or metastatic cervical cancer. This marks the third approved indication for cadonilimab and addresses the critical unmet needs for immune-based therapies for cervical cancer patients in China. The approval is based on the successful results of the COMPASSION-16/AK104-303 study, which demonstrated significant improvements in progression-free survival and overall survival.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1720050803.USD":"安联全方位中国股票基金","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1161":"生物科技","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","BK1574":"生物医药B类股","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","09926":"康方生物","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC"},"translate_title":"康方生物获得NMPA批准卡多尼单抗作为宫颈癌一线治疗药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":0.9},"content_text":"Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer\n    \n\n        Akeso Inc. has announced a significant regulatory milestone, as the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for cadonilimab (PD-1/CTLA-4). This approval allows the use of cadonilimab in combination with platinum-based chemotherapy, with or without bevacizumab, as a first-line treatment for persistent, recurrent, or metastatic cervical cancer. This marks the third approved indication for cadonilimab and addresses the critical unmet needs for immune-based therapies for cervical cancer patients in China. The approval is based on the successful results of the COMPASSION-16/AK104-303 study, which demonstrated significant improvements in progression-free survival and overall survival.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}